Determinants of Hospital Drug Expenditures in Western Europe

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 1993 Aug 6

PMID 10146919

Citations 2

Authors

P Thurmann

S Harder

Affiliations

Soon will be listed here.

Citing Articles

Criteria for the appropriate drug utilisation of immunoglobulin.

Thurmann P, Harder S Pharmacoeconomics. 1996; 9(5):417-29.

PMID: 10160254 DOI: 10.2165/00019053-199609050-00005.

[Structure and activities of drug committees in Germany. Results of a survey of 143 hospitals. Pharmaco-economic Study Group and Rational Drug Therapy of the German Society of Clinical Pharmacology and Therapy].

Harder S, Thurmann P, Steioff A Med Klin (Munich). 1998; 93(2):119-24.

PMID: 9545712 DOI: 10.1007/BF03043288.

References

Redelmeier D, Fuchs V . Hospital expenditures in the United States and Canada. N Engl J Med. 1993; 328(11):772-8. DOI: 10.1056/NEJM199303183281107. View

Rucker T . Quality control of hospital formularies. Pharm Weekbl Sci. 1988; 10(4):145-50. DOI: 10.1007/BF01959422. View

Fletcher C, Metzler D, Rodman J . Patterns of antibiotic use and expenditures during 7 years at a university hospital. Pharmacotherapy. 1990; 10(3):199-204. View

Whittington R, Barradell L, Benfield P . Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life. Pharmacoeconomics. 1992; 3(1):45-82. DOI: 10.2165/00019053-199303010-00006. View

Durand-Zaleski I, Bonnet F, ROCHANT H, Bierling P, Lemaire F . Usefulness of consensus conferences: the case of albumin. Lancet. 1992; 340(8832):1388-90. DOI: 10.1016/0140-6736(92)92568-z. View

Hartmann F . [Drug commission--experiences at a university clinic]. Internist (Berl). 1990; 31(7):475-80. View

Denig P, Haaijer-Ruskamp F, Versluis A, Wesseling H . Prescribing pattern in a Dutch university hospital. J Clin Pharm Ther. 1991; 16(6):423-33. DOI: 10.1111/j.1365-2710.1991.tb00332.x. View

Lipsy R . Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics. 1992; 1(4):265-81. DOI: 10.2165/00019053-199201040-00004. View

Bootman J . Pharmacoeconomics of genetically engineered drugs. Pharmacoeconomics. 1991; 1(1):45-53. DOI: 10.2165/00019053-199201010-00009. View

10.

Sheingold S, Churchill D, Muirhead N, Laupacis A, Labelle R, Goeree R . The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Soc Sci Med. 1992; 34(9):983-91. DOI: 10.1016/0277-9536(92)90129-e. View

11.

Thurmann P, Harder S, Kaiser H, Rietbrock N . Drug utilization and expenditures in a university hospital: a problem for the clinical pharmacologist?. Int J Clin Pharmacol Ther Toxicol. 1992; 30(11):468-9. View

12.

Feely J, Chan R, Cocoman L, Mulpeter K, OConnor P . Hospital formularies: need for continuous intervention. BMJ. 1990; 300(6716):28-30. PMC: 1661902. DOI: 10.1136/bmj.300.6716.28. View

13.

Hirschman S, Meyers B, Bradbury K, MEHL B, GENDELMAN S, Kimelblatt B . Use of antimicrobial agents in a university teaching hospital. Evolution of a comprehensive control program. Arch Intern Med. 1988; 148(9):2001-7. View

14.

Sutters C . The management of a hospital formulary. J Clin Pharm Ther. 1990; 15(1):59-76. DOI: 10.1111/j.1365-2710.1990.tb00357.x. View

15.

Weeks J, Tierney M, Weinstein M . Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991; 325(2):81-6. DOI: 10.1056/NEJM199107113250202. View

16.

Harder S, Thurmann P, Huber T, Rietbrock N . Prescription of drugs not listed in a clinic's pharmacopoeia: supervision by clinical pharmacologists. Eur J Clin Pharmacol. 1991; 40(6):561-4. DOI: 10.1007/BF00279970. View

17.

Woo K, White H . Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Pharmacoeconomics. 1993; 3(3):192-204. DOI: 10.2165/00019053-199303030-00003. View

18.

Dolle W, Schwabe U . [Is openness in the drug market possible?]. Internist (Berl). 1986; 27(1):21-31. View

19.

Jones A, HILL A, Soukop M, Hutcheon A, Cassidy J, Kaye S . Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet. 1991; 338(8765):483-7. DOI: 10.1016/0140-6736(91)90554-3. View

20.

Faulds D, Lewis N, Milne R . Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia. Pharmacoeconomics. 1992; 1(4):231-49. DOI: 10.2165/00019053-199201040-00002. View